Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study
Por:
Puerta-Alcalde, P, O'Keefe, J, Woolstencroft, R, Kaul, S, López, N, Cronin, K, Lim, A, Garcia-Pouton, N, Alvarez, M, Chee, L, Espasa, M, Grafia, I, Suárez-Lledó, M, Smibert, O, Garcia-Vidal, C, Slavin, MA, Yong, MK, Soriano, A and Worth, LJ
Publicada:
1 abr 2025
Ahead of Print:
1 feb 2025
Resumen:
Objectives: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality. Methods: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish hospital. Logistic regression analyses were performed. Results: A total of 547 CDI episodes in cancer patients were documented. Treatment predominantly involved vancomycin (81.5%), followed by metronidazole (15.0%) and fidaxomicin (9.1%). Combined antibiotics were used in 61 (11.2%) episodes. The 90-day recurrence rate was 15.6%. Independent risk factors for CDI recurrence were female sex (OR 2.26, 95% CI 1.13-4.52), age >75 years (OR 2.69, 95% CI 1.30-5.59), dialysis (OR 5.15, 95% CI 1.45-18.27), vomiting at presentation (OR 0.06, 95% CI 0.01-0.55), colonic wall thickening in the CT abdomen (OR 2.42, 95% CI 1.06-5.49) and vancomycin therapy (OR 4.60, 95% CI 1.34-15.84). Overall, 90-day mortality was 22.3%, but attributable mortality was 4.9%. Risk factors for mortality attributed to CDI were age >65 years (OR 15.91, 95% CI 2.64-95.80), previous cerebrovascular disease (OR 20.27, 95% CI 3.12-131.84), antibiotic therapy within the last 30 days (OR 0.17, 95% CI 0.05-0.54), high-output diarrhoea (OR 6.68, 95% CI 1.68-26.56), high CRP-levels (OR 11.60, 95% CI 1.90-70.81) and need for treatment change (OR 6.65, 95% CI 2.20-20.08). Conclusions: CDI recurrence rates among cancer patients remain significant. Nonetheless, fidaxomicin and other preventive strategies are seldom used. We identified several factors that could inform the implementation of these strategies in cancer patients. (c) 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Filiaciones:
:
Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain
Univ Barcelona UB, Barcelona, Spain
O'Keefe, J:
Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia
Woolstencroft, R:
Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia
Kaul, S:
Austin Hlth, Dept Infect Dis & Microbiol, Melbourne, Vic, Australia
López, N:
Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain
Cronin, K:
Royal Melbourne Hosp, Microbiol Dept, Melbourne, Vic, Australia
Lim, A:
Austin Hlth, Haematol Dept, Melbourne, Vic, Australia
Garcia-Pouton, N:
Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain
Alvarez, M:
Hosp Clin IDIBAPS, Ctr Diagnost Biomed, Dept Microbiol, Barcelona, Spain
Chee, L:
Royal Melbourne Hosp, Haematol Dept, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
Espasa, M:
Hosp Clin IDIBAPS, Ctr Diagnost Biomed, Dept Microbiol, Barcelona, Spain
Grafia, I:
Hosp Clin IDIBAPS, Hosp Clin, Barcelona, Spain
Suárez-Lledó, M:
IDIBAPS, Dept Haematol, Barcelona, Spain
Smibert, O:
Austin Hlth, Dept Infect Dis & Microbiol, Melbourne, Vic, Australia
Garcia-Vidal, C:
Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain
Univ Barcelona UB, Barcelona, Spain
CIBERINF CIBER Infect Dis, Barcelona, Spain
Slavin, MA:
Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
Yong, MK:
Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia
Soriano, A:
Hosp Clin IDIBAPS, Dept Infect Dis, Carrer Villarroel 170, Barcelona 08036, Spain
Univ Barcelona UB, Barcelona, Spain
CIBERINF CIBER Infect Dis, Barcelona, Spain
Worth, LJ:
Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
Green Submitted, gold
|